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Strengths and limitations of this study
 ► This study used primary care data from the Clinical 
Practice Research Datalink (CPRD) which are repre-
sentative of the UK primary care population.
 ► Expert-reviewed codelists were developed to define 
both the exposure and the outcome which would re-
duce misclassification bias.
 ► Due to the small sample size of people with general 
practitioner-recorded dementia, we were not able to 
test the relative effectiveness of varenicline versus 
nicotine replacement therapy (NRT) on smoking ces-
sation using regression models.
 ► Data on smokers who purchase over-the-counter 
NRT were not available, and therefore the preva-
lence of NRT might be underestimated.
AbStrACt
Objectives Our primary objective was to estimate 
smoking prevalence and prescribing rates of varenicline 
and nicotine replacement therapy (NRT) in people with and 
without general practitioner (GP)-recorded dementia. Our 
secondary objective was to assess and compare quit rates 
of smokers with versus without GP-recorded dementia 
who were prescribed varenicline or NRT for smoking 
cessation.
Design A retrospective cohort study based on the analysis 
of electronic medical records within the Clinical Practice 
Research Datalink (2007–2015).
Setting 683 general practices in England.
Participants People with and without GP-recorded 
dementia, aged 18 years and have a code indicating that 
they are a current smoker.
Intervention Index prescription of varenicline or NRT 
(from 1 September 2006).
Outcome measures The primary outcomes were 
smoking prevalence and prescribing rates of varenicline 
and NRT (2007–2015). The secondary outcome was 
smoking cessation at 2 years.
results Age and sex-standardised prevalence of smoking 
was slightly higher in people with GP-recorded dementia 
than in those without. There were 235 314 people aged 
18 years and above prescribed NRT or varenicline. Among 
smokers with GP-recorded dementia (N=447), 409 were 
prescribed NRT and 38 varenicline. Smokers with GP-
recorded dementia were 74% less likely (95% CI 64% to 
82%) to be prescribed varenicline than NRT, compared 
with smokers without GP-recorded dementia. Compared 
with people without GP-recorded dementia, people with 
GP-recorded dementia had consistently lower prescribing 
rates of varenicline from 2007 to 2015. Two years after 
prescription, there was no clear evidence for a difference 
in the likelihood of smoking cessation after prescription of 
these medications between individuals with and without 
dementia (OR 1.0, 95% CI 0.8 to 1.2).
Conclusions Between 2007 and 2015, people with 
GP-recorded dementia were less likely to be prescribed 
varenicline than those without dementia. Quit rates 
following prescription of either NRT or varenicline were 
similar in those with and without dementia.
IntrODuCtIOn
Smoking is a leading cause of mortality and 
morbidity worldwide. About 12% of global 
deaths were linked to smoking in 2015.1 
There is substantial evidence that smoking 
is associated with an increased risk of devel-
oping dementia.2 3 For instance, it is esti-
mated that 14% of Alzheimer’s disease (AD) 
cases worldwide are attributable to smoking.4 
Smoking is thought to accelerate the onset of 
dementia mainly via vascular risk factors such 
as narrowing of blood vessels in the heart 
and the brain, thereby triggering oxidative 
stress.4 5
Few studies report smoking prevalence 
among people with dementia. In a cross-sec-
tional analysis of patients treated for AD in 
a neurology clinic during a 2-year period, 
previous smoking prevalence was 29% 
(N=21/72).6 In a case–control study of 
patients with vascular dementia, the rate of 
current tobacco use was 9% (N=17/198) as 
compared with 6% (N=11/199) in the control 
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group.7 Beyond the harmful health effects of smoking in 
people with dementia, there are concerns that smokers in 
this group may have a higher likelihood of fire accidents 
due to their compromised cognitive state.8
Since there are currently no available treatments to 
cure dementia, there is a growing interest in identifying 
modifiable risk factors for reducing the occurrence of the 
disease, to delay dementia onset, and reduce its burden.4 9 
Smoking cessation could potentially decrease the risk or 
slow the development of dementia10 and could improve 
the quality of life of older adults through improved phys-
ical, and mental well-being.9 11 Little is known about 
whether people with dementia are prescribed smoking 
cessation agents and whether they are effective in this 
group.
Based on a Cochrane review of 136 trials, it was reported 
that nicotine replacement therapy (NRT) (compared 
with placebo or no treatment) can help people who make 
a quit attempt to increase their chances of successfully 
stopping smoking (Hartmann-Boyce et al).12 Data from 
observational studies13 14 and meta-analyses of randomised 
controlled trials15 indicate that varenicline is more effec-
tive than single form NRT for smoking cessation in 
the general population. However, it is unclear whether 
varenicline or NRT could help smokers with dementia to 
quit smoking.
Therefore, in this study we aimed to (1) describe the 
rates of smoking prevalence and smoking cessation 
medication prescribing among people with and without 
general practitioner (GP)-recorded dementia in UK 
primary care settings from 2007 to 2015 and (2) assess 
and compare associations of varenicline and NRT on 
smoking cessation in people with GP-recorded dementia, 
compared with those without, at 3, 6, 9 months and 1, 2, 
4 years after first prescription.
MethODS
Data source and population
We conducted a retrospective cohort study using elec-
tronic medical records from 683 general practices in 
England from 2007 to 2015 using data from the Clinical 
Practice Research Datalink (CPRD). Patient data from the 
CPRD are broadly representative of the UK primary care 
population in terms of age, sex and ethnicity.16 These data 
have been validated, audited and quality checked.17 The 
study’s protocol (15_115R) was approved by the Indepen-
dent Scientific Advisory Committee for MHRA Database 
Research (https://www. cprd. com/ isac/).
Code lists
We defined variables using medical and product codes 
within the CPRD. All code lists were developed using a list 
from a previously published study.13 These codelists were 
derived from the the British National Formulary (BNF) 
and the International Classification of Diseases (ICD-10) 
and then agreed on by field experts (DR, KHT). A previous 
systematic review that checked the validity of coding of 
various diagnoses in what was then the General Practice 
Research Database (now CPRD) suggests that coding for 
dementia and Alzheimer’s is relatively accurate.18
Study subjects
During the study period (2007–2015), we included people 
(aged ≥18 years) with information about their smoking 
status (either smokers or non-smokers) for smoking prev-
alence estimates, and we included smokers prescribed 
either varenicline or NRT for prescribing prevalence and 
for comparing quit rates. We used an open cohort design, 
with new patients entering the cohort throughout the 
observation period.
For the primary objective, people were categorised as 
having dementia if: (i) they had ever been diagnosed 
with dementia (based on ICD-10 diagnoses F00-F03), or 
(ii) if they were prescribed dementia medications: (BNF 
chapter 4.11) (see online supplementary eTables 1 and 2 
for a list of all Read and product codes used in this study). 
Then, the earliest record of GP-recorded dementia in 
the CPRD was taken forward ensuring that all records 
used were within the registration period of each patient. 
Patients with no records of the above-mentioned diag-
nosis/prescriptions were considered to have no GP-re-
corded dementia (for clarity, we hence forth refer to this 
as dementia).
For the secondary objective, we constructed a cohort 
of eligible first varenicline/NRT prescriptions (see online 
supplementary eFigure 1 for a flowchart of numbers of 
patients excluded and reasons for exclusion). Within that 
cohort of eligible prescriptions, we considered individ-
uals with dementia to be those with recorded Read codes 
for ever dementia/dementia medications prior to first 
varenicline/NRT prescription; we did this to ensure that 
a diagnosis of dementia preceded the exposure (prescrip-
tion of a smoking cessation medicine).
Variables
Smoking and prescribing prevalence estimates
For smoking prevalence estimates, a patient’s smoking 
status (aged ≥18 years) was defined by a record indicating 
smoking/non-smoking or prescription of NRT/vareni-
cline in that year. In case of missing information about 
smoking, the patient’s smoking status was carried forward 
until there was evidence of a change in smoking status or 
carried backwards if smoking status was only recorded in 
the final year of registration. Records that were outside 
the registration period for each patient were excluded.
exposure
Exposure was defined as prescription of varenicline or 
NRT (eg, patches and so on, on prescription as opposed 
to over-the-counter, hence forth we refer to this as NRT).
Prescriptions used to define exposure groups were 
issued between 1 September 2006 and 31 August 2016, 
with no prior record of use of a related product in the 
preceding 18 months. We used the first treatment episode 
to ensure that intervention groups were ‘new users’ of the 
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Figure 1 Percentage (%) of primary care patients with an 
electronic medical record indicating smoking, from 2007 to 
2015, in people with or without dementia.
medication.19 We did not model multiple and repeated 
prescriptions of smoking cessation medications during 
follow-up because this is likely to be strongly related to 
patient characteristics.
Outcome: smoking cessation
Smoking cessation was defined as having an electronic 
record indicating a non-smoking status. The closest 
smoking record to each follow-up period was selected to 
determine each study participant’s smoking status; that 
is, the most recent smoking record identified between 
cohort entry and each follow-up period (eg, 3 months, 
6 months). People with missing smoking data (beyond 
180 days) were assumed to be continuing smokers20 
which has been previously found to be robust in sensi-
tivity analyses.13
Covariates
Covariates included patients’ age at time of prescription, 
sex, index of multiple deprivation score (IMD), mean 
number of GP visits 1 year prior to first prescription, year 
of first prescription of a smoking cessation medication, 
body mass index (BMI), days registered in the CPRD, the 
Charlson Index (a measure of chronic illness),21 alcohol 
misuse, history of mental disorder or psychoactive medi-
cation prescriptions, evidence of other psychoactive 
medication prescription or other less common psychi-
atric disorders. We used multiple imputation to handle 
missing data on BMI and IMD. This was done using the 
ICE command in Stata where we produced 20 imputed 
datasets (see online supplementary eTables 3). We 
included all exposures, covariates and outcomes in the 
imputation model.22
Follow-up
The secondary outcome was smoking cessation at 2 years, 
and this was also assessed at 3, 6, 9 months and 1 and 4 
years after first prescription of varenicline or NRT.
Statistical analysis
Smoking prevalence
Smoking rates were calculated by dividing the number 
of people with dementia who had Read codes indicating 
current smoking for each year between 2007 and 2015 by 
the total number of people with dementia and a smoking 
status code (indicating current or non/ex-smoking) each 
year between 2007 and 2015. For comparison, smoking 
prevalence was also estimated among people without 
dementia.
Prescribing prevalence
The prevalence of varenicline and NRT prescribing 
among current smokers was calculated by dividing the 
number of prescriptions each year from 2007 to 2015 
(there were no varenicline prescriptions for patients with 
dementia in 2006) by the number of current smokers 
in each year. Prevalence was estimated for people with 
and without dementia. Individuals with missing smoking 
information were excluded from the denominators.
Association of varenicline and NRT prescriptions with smoking 
cessation
We had originally planned to compare the effectiveness 
of NRT and varenicline for smoking cessation in individ-
uals with dementia. However, given the small numbers 
of individuals prescribed varenicline, we had insufficient 
power to conduct this analysis. Therefore, we compared 
the effectiveness of being prescribed either varenicline or 
NRT on smoking cessation in individuals with dementia 
compared with individuals without dementia. This was 
determined by estimating quit rates at each follow-up 
period for individuals prescribed either of these medi-
cations. This was calculated by dividing the number of 
non-smokers in each group by the total number of people 
in that group at each follow-up period. All analyses were 
conducted using Stata V.14 MP.
Patient and public involvement
This study was based on the analysis of anonymised 
primary care data. No patients were involved during the 
design and analysis of this study.
reSultS
Smoking prevalence and smoking cessation medication 
prescribing estimates
Unadjusted smoking prevalence among people with 
dementia steadily decreased from 11% (N=2965/27 
432 in 2007 to 7% (N=2690/36 249) in 2015 (figure 1). 
These estimates were consistently lower than in people 
without dementia, 26% (N=1 010 530/3 860 169) in 2007 
and 21% (N=628 444/3 068 743) in 2015, respectively 
(see online supplementary eTable 4). However, after age 
and sex standardisation, the smoking prevalence among 
people with dementia was slightly higher than in people 
without (see online supplementary eFigure 2).
The rate of NRT prescribing in people without dementia 
was 7% (68 935/1 010 530) in 2007 which decreased to 2% 
(N=13 626/628 444) by 2015, whereas NRT prescribing 
rates among people with dementia increased during the 
same period. Compared with people without dementia, 
people with dementia had lower prescribing rates of 
varenicline (figure 2).
by copyright.
 o
n
 Septem
ber 19, 2019 at University of Bristol Library. Protected
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-027569 on 30 August 2019. Downloaded from 
4 Itani T, et al. BMJ Open 2019;9:e027569. doi:10.1136/bmjopen-2018-027569
Open access 
Figure 2 Prescription prevalence of varenicline or NRT in 
primary care, from 2007 to 2015, in smokers with dementia, 
compared with smokers without dementia. NRT, nicotine 
replacement therapy.
Smoking cessation amongst individuals prescribed nrt and 
varenicline
Of the 235 314 people included in this analysis, 447 
were people with dementia, whereas 234 867 were 
people without (see online supplementary eFigure 1). 
Overall, 159 736 smokers were prescribed NRT and 
75 578 prescribed varenicline (table 1). The mean age of 
people with dementia at the time of smoking medication 
prescription was about 72 years (SD=12.6), while that of 
people without dementia was 46 years (SD=14.8) People 
with dementia were about 25 years older, had more GP 
visits 1 year prior to the first prescription, suffered from 
more comorbidities and received more mental health-re-
lated prescriptions than those without dementia (table 1).
Smokers with dementia were 74% (95% CI 64% to 
82%) less likely to be prescribed varenicline than NRT, 
compared with smokers without dementia (see online 
supplementary eTable 5). The proportion of people 
with and without dementia who quit smoking after 
being prescribed either varenicline or NRT increased 
throughout the study’s follow-up period (3 months to 
4 years). At 2-year follow-up, people with dementia were 
more likely to quit smoking (30.6%, 95% CI 25.8% to 
35.1%) than those without (25.7%, 95% CI 25.4% to 
25.8%) when prescribed either varenicline or NRT 
(figure 3) (see online supplementary eTable 6). However, 
after adjusting for all covariates, we found no evidence 
for a difference in quit rates between individuals with 
and without dementia (OR=1.0, 95% CI 0.81 to 1.23) (see 
online supplementary eTable 7).
DISCuSSIOn
People with dementia were less likely to be prescribed 
varenicline compared with those without dementia. There 
was no clear evidence for a difference in quit rates in indi-
viduals with and without dementia following prescription 
of NRT or varenicline.
A strength of this study is that we used primary care data 
from the CPRD which are representative of the UK primary 
care population.16 Hence, smoking rates in people with 
dementia in this study are likely to be generalisable to the 
dementia population in the UK and in similar countries. 
Additionally, we used expert-reviewed codelists to define 
both the exposure and the outcome which would reduce 
misclassification bias (ie, classifying people with dementia 
as people without and vice versa).
There are several limitations to this research. Due to the 
small sample size of people with dementia, we were not 
able to test the relative effectiveness of varenicline versus 
NRT on smoking cessation using regression models. We 
had no data on smokers who purchase over-the-counter 
NRT, therefore we might be underestimating the prev-
alence of NRT use, particularly among people without 
dementia. Hence, it is likely that the prevalence of NRT 
use among people without dementia is larger than the 
prevalence of NRT prescribing in this study. Moreover, 
outcome definition (smoking vs non-smoking status) was 
based on self-reported data rather than biochemical veri-
fication of smoking status. Additionally, social desirability 
bias may occur when unsuccessful quitters don’t disclose 
their smoking status truthfully. We also relied on point 
estimates (ie, smoking status reported at a single time-
point) for making conclusions about smoking status. This 
may not have captured long-term abstinence. In other 
words, it is possible that smoking status may have fluc-
tuated between GP visits. A further limitation is having 
no information about patient adherence in taking their 
prescribed smoking cessation medications.
We are not aware of previous population-based studies 
that estimated the smoking rates among people with 
dementia as the available evidence has been limited to 
small cross-sectional studies. For instance, a community 
study in China found that about 17% (N=69/186) of 
the elderly sample with dementia were current smokers 
compared with 25% (N=415/1664) in people without 
dementia.23 Results from the Toyama dementia survey 
in Japan show that only 4% of people with dementia 
smoked compared with 10% in those without.24 This high 
variability in the results points to the need for larger and 
more representative studies in people with dementia to 
be conducted. Meanwhile, we found that smoking prev-
alence has decreased steadily among people without 
dementia, from 26% in 2007 to 21% in 2015. This was 
fairly similar to the general population in England as 
evidenced by results from the Smoking Toolkit Study 
(24.2% in 2007 to 18.7% in 2015)25 and therefore speaks 
to the external validity of our study.
We observed a low prevalence of varenicline prescribing 
during our study period in people with dementia. Our 
estimate for individuals without dementia was consis-
tent with findings from a previous study that examined 
the use of varenicline for smoking cessation treatment 
in UK primary care using data from THIN database in 
2011. Compared with our results from that year, our esti-
mates appear slightly lower (1.1% vs 1.8% in the THIN 
study).26 While NRT prescribing rates increased from 4% 
in 2007 to 5% in 2015 in people with dementia, these 
rates declined over time in people without dementia. A 
recent report from the British Lung Foundation found 
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Figure 3 Percentage (%) of people with an electronic 
medical record indicating smoking cessation at up to 2 years 
follow-up, in people with and without dementia.
that NRT prescribing through primary care in England 
has dropped about 75% during the last 10 years. That was 
mainly due to cuts to public health funding that would 
have adversely impacted specialist stop smoking services.27
Our study is among the first to investigate longer term 
smoking cessation after being prescribed varenicline 
and NRT among individuals with dementia in a real 
world setting. Our results suggest that both varenicline 
and NRT could produce long-term smoking cessation 
in people with dementia as they do in those without. 
Almost one-third of smokers with dementia quit smoking 
after 2-year follow-up. Regardless of the smoking cessa-
tion medication prescribed to people with dementia, it 
is important to acknowledge that achieving smoking 
cessation in this group may carry health benefits which 
would potentially improve their general health status and 
and/or extend life expectancy.28 This should ideally be 
coupled with improving diet quality and increasing phys-
ical activites that may shield quitters from weight gain 
after smoking cessation.29
It is not clear why individuals with dementia are less 
likely to be prescribed varenicline than NRT compared 
with individuals without. Previous clinical and observa-
tional studies have established that varenicline is supe-
rior to single form NRT in achieving smoking cessation 
in different groups.13 30 31 Additionally, varenicline did 
not seem to be associated with an increased risk of docu-
mented cardiovascular events, depression or self-harm 
when compared with NRT in primary care in England.32 
On the other hand, a recent study based on CPRD data 
concluded that NRT appears to increase cardiovascular 
events for patients prescribed NRT, compared with those 
receiving smoking cessation advice after 52 weeks of 
follow-up.33 This was consistent with the evidence shown 
by a meta-analysis of 120 studies involving 177 390 indi-
viduals.12 It is possible that GPs are less likely to prescribe 
varenicline to individuals with dementia because of lower 
likelihood of adherence; in a recent systematic review of 
the literature, older patients with dementia were found to 
have a low level of medication adherence.34
In summary, age-adjusted and sex-adjusted smoking 
prevalence among individuals with dementia was similar 
to those without dementia and smoking cessation rates 
were similar following prescription of smoking cessation 
medications between these groups. However, individuals 
with dementia were less likely to be prescribed vareni-
cline than individuals without dementia.
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